STOCK TITAN
  1. Home
  2. Sec-filings
  3. MIRM
  4. [Form 4] Mirum Pharmaceuticals, Inc. Insider Trading Activity

Mirum Pharmaceuticals (MIRM) director granted new options and deferred stock units

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Mirum Pharmaceuticals director Laurent Fischer received new equity awards in the form of deferred stock units and stock options. The filing shows a grant of 1,980 deferred stock units and 3,772 stock options, each tied to Mirum common stock.

The stock options carry an exercise price of $101.00 per share and expire on June 14, 2036. Both the options and deferred stock units vest on the first anniversary of the June 15, 2026 grant date, and in any case are fully vested by the date of Mirum’s 2027 annual stockholder meeting.

Each deferred stock unit represents a right to receive one share of common stock. Vested deferred stock units will be settled in stock upon the earlier of a change in control of Mirum or within 60 days after Fischer’s separation from service with the company.

Positive

  • None.

Negative

  • None.
Insider Fischer Laurent
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 3,772 $0.00 --
Grant/Award Deferred Stock Units 1,980 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 3,772 shares (Direct, null); Deferred Stock Units — 1,980 shares (Direct, null)
Footnotes (1)
  1. The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.
Deferred stock units granted 1,980 units Grant to Laurent Fischer on June 15, 2026
Stock options granted 3,772 options Grant to Laurent Fischer on June 15, 2026
Option exercise price $101.00 per share Stock option grant to Fischer
Option expiration date June 14, 2036 Stock option term for Fischer grant
Deferred units underlying shares 1,980 shares Each unit equals one Mirum common share
Options underlying shares 3,772 shares Underlying Mirum common stock for options
Deferred Stock Units financial
"Each deferred stock unit represents a contingent right to receive one share"
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
stock options financial
"The filing shows a grant of 1,980 deferred stock units and 3,772 stock options"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"The stock options carry an exercise price of $101.00 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
change in control financial
"paid out upon the earliest to occur of (i) a change in control of the Issuer"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
separation from service financial
"within 60 days following separation from service with the Issuer"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fischer Laurent
(Last)(First)(Middle)
C/O MIRUM PHARMACEUTICALS, INC.
989 E HILLSDALE BLVD., SUITE 300
(Street)
FOSTER CITY CALIFORNIA 94404
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$10106/15/2026A3,772 (1)06/14/2036Common Stock3,772$03,772D
Deferred Stock Units(2)06/15/2026A1,980 (2) (2)Common Stock1,980$01,980D
Explanation of Responses:
1. The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
2. Each deferred stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each vested deferred stock unit will be paid out in the Issuer's common stock upon the earliest to occur of (i) a change in control of the Issuer and (ii) within 60 days following separation from service with the Issuer.
/s/ Judit Ryvkin, Attorney-in-Fact06/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Mirum Pharmaceuticals (MIRM) director Laurent Fischer report on this Form 4?

Laurent Fischer reported receiving equity awards in the form of deferred stock units and stock options. The grants are compensation-related, giving him rights to Mirum common stock upon vesting and, for the options, upon future exercise at a fixed price.

How many deferred stock units did Laurent Fischer receive from Mirum Pharmaceuticals (MIRM)?

Laurent Fischer received 1,980 deferred stock units tied to Mirum common stock. Each unit converts into one share when settled, subject to vesting and specific payout triggers such as a change in control or separation from service with the company.

What are the main terms of Laurent Fischer’s new stock options at Mirum Pharmaceuticals (MIRM)?

Fischer received 3,772 stock options with an exercise price of $101.00 per share, expiring June 14, 2036. These options are exercisable only after vesting, giving him the right, but not obligation, to buy Mirum common shares at that fixed price.

When do Laurent Fischer’s Mirum (MIRM) equity awards vest?

Both the deferred stock units and stock options vest on the first anniversary of the June 15, 2026 grant date. They will in any case be fully vested by the date of Mirum Pharmaceuticals’ 2027 annual stockholder meeting, according to the disclosed vesting terms.

How and when are Laurent Fischer’s Mirum (MIRM) deferred stock units paid out?

Each vested deferred stock unit is settled in Mirum common stock. Payment occurs at the earlier of a change in control of Mirum Pharmaceuticals or within 60 days after Fischer’s separation from service with the company, as specified in the award terms.

Are Laurent Fischer’s Mirum (MIRM) Form 4 transactions open-market buys or sales?

No, the reported transactions are grants of equity awards, not open-market trades. The Form 4 classifies them as grant or award acquisitions, reflecting compensation arrangements rather than discretionary buying or selling of Mirum shares in the market.